The main objective of the GMP CDC LAB project is the marketing of active pharmaceutical ingredients (APIs) and pharmaceutical preparations (MPs) containing cannabinoids. With the objective of starting sales in June 2023.
The APIs will be offered to Swiss and European pharmaceutical companies, pharmacies and medical centers.
Contact us for more information.